9/1/2021

Potassium Chloride Injection

Products Affected - Description

- Potassium chloride injection, Fresenius Kabi, 2 mEq/mL, 10 mL vial, 25 count, NDC 63323-0965-10
- Potassium chloride injection, Fresenius Kabi, 2 mEq/mL, 20 mL vial, 25 count, NDC 63323-0965-20
- Potassium chloride injection, Fresenius Kabi, 2 mEq/mL, 30 mL vial, 25 count, NDC 63323-0967-30
- Potassium chloride injection, Pfizer, 2 mEq/mL, 10 mL vial, 25 count, NDC 00409-6651-06
- Potassium chloride injection, Pfizer, 2 mEq/mL, 20 mL vial, 25 count, NDC 00409-6653-05

Reason for the Shortage

- Only potassium chloride injection vials are affected by this shortage.
- Pfizer has potassium chloride injection on shortage due to increased demand.
- Fresenius Kabi has potassium chloride injection on shortage due to a manufacturing delay.

Available Products

- Potassium chloride injection, Fresenius Kabi, 2 mEq/mL, 5 mL vial, 25 count, NDC 63323-0965-05
- Potassium chloride injection, Pfizer, 2 mEq/mL, 5 mL vial, 25 count, NDC 00409-6635-01

Estimated Resupply Dates

- Pfizer has potassium chloride 20 mEq/10 mL vials and 40 mEq/20 mL vials on back order and the company estimates a release date of September 2021.
- Fresenius Kabi has potassium chloride 20 mEq/10 mL vials on back order and the company estimates a release date of early-October 2021. The 40 mEq/20 mL vials are on back order and the company estimates a release date of late-September 2021. The 60 mEq/30 mL vials are on back order and the company estimates a release date of mid-October 2021.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.